Research & Development
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Moonlake Aims To Defy The Single-Product Risk
The group is pushing sonelokimab into pivotal trials in two indications and starting from scratch in three more. What comes after that?
Pipeline Watch: Six Approvals And 26 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Moeller Looks To Prove BenevolentAI’s Doubters Wrong
The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act
BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
Chinese ADC Developers Unveil More Target Combos In Bispecific Drive
Chinese developers are racing to roll out bispecific ADCs with different target combinations, while a Biokin/SysImmune executive estimates more than $20bn in annual sales for the company's BMS-partnered EGFR x HER3 candidate, as R&D in the field continues to surge ahead in China.
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Ionis Could Be A Factor In MASH With Positive Phase II Data
Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.
BeiGene’s Oncology Market 'Disruption' Gains Pace Despite Tevimbra Travails
The Sino-American company believes faster, lower-cost R&D and competitive pricing and access will give it an edge in oncology. Its chief commercial officer for North America and Europe told Scrip how it is now looking to repeat the success of Brukinsa and finally launch its much-delayed PD-1 inhibitor Tevimbra.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
In Competitive DLBCL Setting, Pfizer Goes Old School With Adcetris
The ECHELON-3 trial in third-line diffuse large B-cell lymphoma showed positive topline results regardless of CD30 expression, and the drug maker intends to take the data to the FDA.
Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Acadia's Nuplazid Expansion Bid Bites The Dust
Nuplazid is a decent earner for the US biotech in psychosis caused by Parkinson’s disease but following previous failures in Alzheimer's and dementia, the drug has now proved a dud for treating the negative symptoms of schizophrenia.
Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?
Troubled since a miss in hidradenitis suppurativa last fall, Acelyrin’s izokibep succeeded in a psoriatic arthritis trial, but will the drug compete well against other IL-17 inhibitors?
Alumis Looks To Stand Out From The TYK2 Crowd With Psoriasis Data
The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.